We are excited to publish on our Phage-mimicking nanoparticles efficiently tackling Group A Streptococcus infections in mouse wound infection models in RSC Nanoscale Advances (https://pubs.rsc.org/en/content/articlepdf/2024/NA/D3NA00620D). Thank you to Prof. Frank Castellino, Prof. Victoria Ploplis, and Deborah Donahue of the W.M. Keck Transgene Center for the in vivo studies. Thanks to Prof. Shaun Lee’s lab (Biology) for sharing their antimicrobial peptide library with us. This was truly a team effort by the technical staff and undergraduate researchers with the graduate student (Johanna Olesk) to get the data necessary to publish this work. The Indiana-CTSI project development team fund initiated this collaboration. The work was sustained by the Berthiaume Institute for Precision Health funding and the American Cancer Society’s Institutional Research Grant. This work highlights the quality research contributions made by Notre Dame Undergraduates. Conor Sheehan, Kevin Armknecht, and Zach Bennett are all undergraduate researchers. Conor Sheehan (NURF’22) and Kevin Armknecht (NURF’23) had summer undergraduate research fellowships from NDNnano. Johanna Olesk (MS-BioE’23) had a Materials Science and Engineering Fellowship in 2023. We are thankful for the support from BIPH UNDresearch and CTSI Indiana for bringing this publication to fruition. Congratulations to all the authors for this fantastic work.
Jan 29
Phage-Mimicking Antibacterial Nanoparticles Tackle Group A Streptococcal Infections In Vivo
Categories:
American Cancer Society, Berthiaume Institute for Precision Health, Hybrid nanoparticles, Indiana Clinical Translational Sciences Institute (I-CTSI), multidrug resistance
by Prakash
This post has no tag
Recent Posts
- Military Health Sciences Research Symposium 2024. (Aug 26-29, 2024, Kissimmee FL) August 30, 2024
- Sustained and Controlled Antibiotics Release for Prolonged Antibacterial Action Against MRSA, and Pseudomonas aeruginosa August 21, 2024
- Precision Health and Diagnostics Session Chair at Techconnect World Innovation Conference (2024) June 19, 2024
- MTEC Annual meeting in Baltimore MD (May 24, 2024) May 24, 2024
- Nallathamby Lab’s Kevin Armknecht is Invited to Present at the Midwest Microscopy and Microanalysis Workshop 2024 May 7, 2024
Archives
Categories
NIH Funding Opportunities
- Notice of Special Interest (NOSI): Autoimmune Inner Ear Disease (Clinical Trials Not Allowed) October 23, 2024Notice NOT-DC-25-003 from the NIH Guide for Grants and Contracts
- Notice of Future Other Transactions (OT) Research Opportunity Announcement for All of Us Research Program Biobank October 23, 2024Notice NOT-PM-25-001 from the NIH Guide for Grants and Contracts
- Pilot projects to enhance utility and usage of data sets from the Molecular Transducers of Physical Activity Consortium (MoTrPAC) (R03 Clinical Trials Not allowed) October 23, 2024Funding Opportunity RFA-RM-24-011 from the NIH Guide for Grants and Contracts. The Molecular Transducers of Physical Activity Consortium (MoTrPAC) has made data available through the MoTrPAC Data Hub (http://MoTrPAC-data.org). The purpose of this NOFO is to announce the availability of funding to support novel approaches for analyzing MoTrPAC data, to generate hypotheses and catalyze discoveries; […]
- BRAIN Initiative: Brain Behavior Quantification and Synchronization- Next Generation Sensor Technology Development (U01 Clinical Trial Optional) October 23, 2024Funding Opportunity RFA-MH-26-140 from the NIH Guide for Grants and Contracts. This NOFO solicits applications for next generation sensor and bioelectronic device development that will synchronize with brain recordings. The sensor and neural recording data will be used to generate new computational models of behavior in human and animal models. There has been a lack […]
- NINDS Policy for applications requesting $500,000 or more in direct costs in any year (excluding consortium F and A)on NIH Notices of Funding Opportunities, PAR-22-242 and PAR-22-243. October 23, 2024Notice NOT-NS-25-004 from the NIH Guide for Grants and Contracts
- Human Virome Program: Developing novel and innovative tools to interrogate and annotate the human virome (U01 Clinical Trial Not Allowed) October 23, 2024Funding Opportunity RFA-RM-24-009 from the NIH Guide for Grants and Contracts. The Common Fund Human Virome Program aims to extensively characterize the human virome and create tools, models, and methods that will enable an in-depth study of its variation in relation to host factors and its influence on health and disease. The purpose of this […]
- Centers for Accelerating Phage (Bacteriophage) Therapy to Combat ESKAPE Pathogens (CAPT-CEP) (P01 Clinical Trial Not Allowed) October 23, 2024Funding Opportunity RFA-AI-24-069 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to solicit applications to establish Centers for Accelerating Phage Therapy to Combat ESKAPE Pathogens (CAPT-CEP). These Centers will focus on developing preclinical assays, tools, and models for robust phage therapy research and development (R […]
- NIDCR Drug, Biologic, Device and/or Procedure Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required) October 23, 2024Funding Opportunity PAR-25-057 from the NIH Guide for Grants and Contracts. To support UG3/UH3 phased, cooperative agreement research applications to plan and implement clinical trials within the mission of the National Institute of Dental and Craniofacial Research (NIDCR)
- Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp Clinical Trial NOT Allowed) October 22, 2024Funding Opportunity PA-25-212 from the NIH Guide for Grants and Contracts. Through this I-Corps at NIH program Notice of Funding Opportunity (NOFO), NIH and CDC provide administrative supplement awards to active SBIR (NIH and CDC) and STTR Phase I (NIH only) grantees/awardees. The I-Corps at NIH mission is to empower entrepreneurs in developing and validating […]
- Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed) October 22, 2024Funding Opportunity PAR-25-059 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders. This FOA is part of a suite of Innovation Grants […]
Recent Comments